SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary

NCT06269120 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the effects of the oral medication semaglutide on blood sugar, weight, and heart disease risk in adults with type 2 diabetes in Hungary.

Status Recruiting Currently enrolling participants.

Type Observational

Participants 470 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2024-09 · est. completion 2026-03

Where 1 site · Hungary

What this study is testing ClinicalTrials.gov NCT06269120 ↗

Description as written by the study sponsor.

Participant will get oral semaglutde as prescribed by the study doctor. The study will last for about 26 ± 4 weeks (5 to 7 months). Participant will be asked to complete a questionnaire about how they take oral semaglutide tablets during normal scheduled visit with doctor. Participant will also be asked questions about health and their diabetes treatment and lab tests as part of normal doctor's appointment.

Treatments tested

Oral Semaglutide Drug

Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.

Main thing measured	Glycated haemoglobin (HbA1c ) reduction greater than or equal to (≥) 0.5%-point and body weight reduction ≥ 5%
Sponsor	Novo Nordisk A/S
Conditions studied	Type 2 Diabetes
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06269120 ↗